Metformin: The safest hypoglycaemic agent in chronic kidney disease?

Nephron - Clinical Practice

Volumn 118, Issue 4, 2011, Pages

  Nye, Helen J ^a   Herrington, William G ^b  

^a NORTH BRISTOL NHS TRUST   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Lactic acidosis; Metformin; Renal impairment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG UTILIZATION; FLUID RETENTION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; HYPOVOLEMIA; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEPSIS; SIDE EFFECT; WEIGHT GAIN;

ACIDOSIS, LACTIC; ANIMALS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; METFORMIN;

EID: 79851514348     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000323739     Document Type: Review

References (11)

1. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-856.
2. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL: Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399. (Pubitemid 351664540)
3. Currie CJ, Poole CD, Gale EA: The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
4. NICE Clinical Guideline CG87 (May 2009): Type 2 diabetes -newer agents (a partial update of CG66).
5. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB: Metformin and lactic acidosis: Cause or coincidence? A review of case reports. J Intern Med 2004; 255: 179-187. (Pubitemid 38241362)
6. Lalau JD, Race JM: Lactic acidosis and metformin therapy: Searching for a link with metformin in reports of 'metformin-associated lactic acidosis'. Diabetes Obes Metab 2001; 3: 195-201. (Pubitemid 32785329)
7. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes. Cochrane Database Syst Rev 2010; 4: CD002967.
8. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR: Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycaemia. Diabetes Care 2008; 31: 2086-2091.
9. Mani MK: Metformin in renal failure -weigh the evidence. Nephrol Dial Transplant 2009; 24: 2287-2288.
10. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. BMJ 2007; 335: 497-506.
11. Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG: Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995; 35: 1094-1102.